Lutein and zeaxanthin are carotenoids sourced from plants that settle specifically into the macula — the small central zone of the retina that handles sharp, detailed vision. Together they make up the macular pigment, screening out damaging blue light and offering antioxidant cover to the light-sensitive cells beneath. It's this specific concentration in eye tissue that's driven more than two decades of focused research on the pair.
The AREDS2 Study
The Age-Related Eye Disease Study 2 (AREDS2) was a large, NIH-funded randomized controlled trial involving 4,203 participants aged 50–85 who already had intermediate age-related macular degeneration (AMD) or advanced AMD in one eye. Researchers tested whether adding lutein/zeaxanthin, omega-3 fatty acids, or both to the original AREDS antioxidant formula would further reduce the risk of progressing to advanced AMD.
The topline result: adding lutein/zeaxanthin or omega-3s to the AREDS formula did not significantly reduce AMD progression risk across the full study group. However, a few more specific findings stood out:
| Finding | Detail |
|---|---|
| Beta-carotene replacement | Replacing beta-carotene with lutein/zeaxanthin in the formula was found to be safer, avoiding the increased lung cancer risk beta-carotene poses to smokers and former smokers. |
| Low dietary intake subgroup | Participants with the lowest baseline dietary intake of lutein/zeaxanthin saw a statistically significant 26% reduction in progression to advanced AMD when supplementing. |
| 10-year follow-up | A later follow-up study found a modest but statistically significant reduction in late AMD progression associated with lutein/zeaxanthin over the long term. |
An Important Distinction: Who This Research Applies To
It's worth being precise here: AREDS2 studied people who already had intermediate or advanced AMD in at least one eye — it was designed to test whether the formula could slow progression in an existing condition, not to test whether it prevents AMD from developing in healthy eyes. The National Eye Institute's guidance reflects this: the AREDS2 formula is generally recommended for people already diagnosed with intermediate or advanced AMD, based on their eye doctor's assessment, rather than as a general prevention strategy for the broader population.
What This Means Practically
If you've been diagnosed with intermediate AMD, the AREDS2 formula is a research-backed option worth discussing with your eye doctor, who can advise on whether it's appropriate for your specific diagnosis. If you don't have a diagnosed macular condition, lutein and zeaxanthin still have a plausible biological rationale (their role in macular pigment) and are found naturally in leafy greens and colorful vegetables, but general supplementation in the absence of a diagnosis hasn't been shown to prevent AMD from developing in the first place — regular eye exams remain the primary tool for early detection.
Sources
- Age-Related Eye Disease Study 2 Research Group, "Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration," JAMA, 2013.
- Chew, E.Y. et al., 10-year follow-up report on AREDS2 lutein/zeaxanthin and lung cancer/AMD outcomes, JAMA Ophthalmology, 2022.
- National Eye Institute, "Age-Related Macular Degeneration (AMD)," nei.nih.gov.
This article is for general educational purposes and summarizes findings from published research. It is not medical advice and does not describe the effects of any specific product.